Skip to content
2000
Volume 24, Issue 24
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Sialic acid residues that make part of the cell surface repertoire of carbohydrate residues are implicated in various physiological processes and human pathologies. Sialidases, or neuraminidases, are the enzymes that are able to cleave and release the sialic acid residues, while trans-sialidases can transfer the residues from donor to acceptor molecules. They are important for processing the surface glycolipids and glycoproteins. Therapeutic potential of pharmacological sialidases inhibition is currently actively studied. Knowledge and expertise gained from genetic defects leading to human sialidase deficiency can be used for designing such drugs. In this review, we discuss the current progress in studying sialidases and their inhibitors and the relevance of these studies to developing novel therapeutic approaches. In vitro studies suggest that some sialidase inhibitors might be useful therapeutics for treating sialidosis, cancer, infections, immune diseases, atherosclerosis and other pathologies. Consequently, there is a field for further research and development. A thorough investigation of human sialidases is therefore crucial to human health.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612824666180910125051
2018-07-01
2025-10-29
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612824666180910125051
Loading

  • Article Type:
    Review Article
Keyword(s): desialylation; glycolipids; sialic acid; Sialidase; sialidase inhibitors; trans-sialidase
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test